- Home
- CYH vs CRVS Comparison
CYH vs CRVS Comparison
Compare CYH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CRVS
- Stock Information
- Founded
- CYH 1985
- CRVS 2014
- Country
- CYH United States
- CRVS United States
- Employees
- CYH N/A
- CRVS N/A
- Industry
- CYH Hospital/Nursing Management
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- CRVS Health Care
- Exchange
- CYH Nasdaq
- CRVS Nasdaq
- Market Cap
- CYH 348.9M
- CRVS 305.4M
- IPO Year
- CYH 1991
- CRVS 2016
- Fundamental
- Price
- CYH $2.74
- CRVS $4.85
- Analyst Decision
- CYH Hold
- CRVS Strong Buy
- Analyst Count
- CYH 8
- CRVS 4
- Target Price
- CYH $3.57
- CRVS $15.00
- AVG Volume (30 Days)
- CYH 4.3M
- CRVS 451.5K
- Earning Date
- CYH 07-23-2025
- CRVS 08-07-2025
- Dividend Yield
- CYH N/A
- CRVS N/A
- EPS Growth
- CYH N/A
- CRVS N/A
- EPS
- CYH N/A
- CRVS N/A
- Revenue
- CYH $12,647,000,000.00
- CRVS N/A
- Revenue This Year
- CYH N/A
- CRVS N/A
- Revenue Next Year
- CYH $2.25
- CRVS N/A
- P/E Ratio
- CYH N/A
- CRVS N/A
- Revenue Growth
- CYH 0.81
- CRVS N/A
- 52 Week Low
- CYH $2.24
- CRVS $2.54
- 52 Week High
- CYH $6.29
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CYH 44.28
- CRVS 62.34
- Support Level
- CYH $2.43
- CRVS $4.05
- Resistance Level
- CYH $2.55
- CRVS $5.05
- Average True Range (ATR)
- CYH 0.12
- CRVS 0.25
- MACD
- CYH 0.03
- CRVS 0.04
- Stochastic Oscillator
- CYH 88.75
- CRVS 81.65
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).